Larimar Therapeutics, Inc. (NASDAQ:LRMR) Expected to Earn FY2026 Earnings of ($2.65) Per Share

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Research analysts at Leerink Partnrs issued their FY2026 earnings per share estimates for shares of Larimar Therapeutics in a research note issued on Wednesday, April 3rd. Leerink Partnrs analyst J. Park forecasts that the company will post earnings of ($2.65) per share for the year. Leerink Partnrs has a "Outperform" rating on the stock. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.17) per share. Leerink Partnrs also issued estimates for Larimar Therapeutics' FY2027 earnings at ($2.41) EPS and FY2028 earnings at ($1.75) EPS.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its earnings results on Thursday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.05).

A number of other equities analysts have also issued reports on the company. Citigroup upped their target price on Larimar Therapeutics from $4.50 to $10.00 and gave the company a "buy" rating in a research report on Tuesday, February 13th. SVB Leerink started coverage on Larimar Therapeutics in a report on Wednesday. They issued an "outperform" rating and a $25.00 price target for the company. JMP Securities reiterated a "market outperform" rating and issued a $25.00 price target on shares of Larimar Therapeutics in a report on Friday, March 15th. Finally, Lifesci Capital reiterated an "outperform" rating on shares of Larimar Therapeutics in a report on Tuesday, February 20th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $18.50.

Larimar Therapeutics Stock Down 5.8 %

Shares of LRMR traded down $0.45 during trading on Thursday, reaching $7.27. The company's stock had a trading volume of 365,796 shares, compared to its average volume of 607,243. The company has a fifty day moving average of $8.91 and a two-hundred day moving average of $5.52. Larimar Therapeutics has a twelve month low of $2.18 and a twelve month high of $13.68. The company has a market cap of $463.83 million, a price-to-earnings ratio of -9.34 and a beta of 0.93.

Institutional Investors Weigh In On Larimar Therapeutics

Hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System purchased a new stake in Larimar Therapeutics in the 2nd quarter worth about $27,000. UBS Group AG increased its holdings in shares of Larimar Therapeutics by 8,152.8% during the 1st quarter. UBS Group AG now owns 5,942 shares of the company's stock valued at $27,000 after acquiring an additional 5,870 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Larimar Therapeutics by 4,797.5% during the 2nd quarter. Wells Fargo & Company MN now owns 9,795 shares of the company's stock valued at $31,000 after acquiring an additional 9,595 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Larimar Therapeutics by 836.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 11,822 shares of the company's stock valued at $38,000 after acquiring an additional 10,560 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Larimar Therapeutics during the 3rd quarter valued at about $44,000. 91.92% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director James E. Flynn acquired 4,290,617 shares of the business's stock in a transaction dated Friday, February 16th. The stock was acquired at an average price of $8.74 per share, for a total transaction of $37,499,992.58. Following the completion of the acquisition, the director now directly owns 6,151,406 shares in the company, valued at approximately $53,763,288.44. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.30% of the company's stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.